Mepivacaine Instillation Eases IUD Insertion Pain

Intrauterine instillation of the anesthetic mepivacaine demonstrated a significant reduction in pain experienced during the insertion of intrauterine devices (IUDs), according to findings from a Swedish randomized trial. The study, published in the journal Contraception, involved 100 participants undergoing IUD insertion. Researchers measured pain using a visual analog scale (VAS), where 0 mm represents no pain and 100 mm represents the worst imaginable pain. The mean pain score during IUD placement in the mepivacaine group was 43.8 mm, compared to 68.5 mm in the placebo group, indicating a substantial difference in perceived pain levels. This represents a statistically significant reduction in pain for individuals receiving the anesthetic instillation.

The trial employed a double-blind, placebo-controlled design, ensuring that neither the participants nor the researchers administering the treatment knew who was receiving mepivacaine and who was receiving the saline placebo. This methodology is considered the gold standard for clinical trials, minimizing bias and strengthening the validity of the results. Participants were randomized into two groups: one receiving 20 mL of 1% mepivacaine instilled into the uterine cavity 5 minutes prior to IUD insertion, and the other receiving an equal volume of sterile saline as a placebo. The primary outcome measured was the VAS pain score during the IUD insertion procedure itself. Secondary outcomes included pain experienced immediately after insertion, 1 hour after, and 24 hours after the procedure, as well as patient satisfaction with the pain management method.

Results for the secondary outcomes also favored the mepivacaine group. The mean pain score immediately after insertion was 30.2 mm for the mepivacaine group versus 48.9 mm for the placebo group. One hour post-insertion, the scores were 15.5 mm and 25.1 mm, respectively. Twenty-four hours after insertion, the pain scores were minimal in both groups but still showed a trend towards lower pain in the mepivacaine group (5.2 mm vs. 8.9 mm). Patient satisfaction surveys indicated that 85% of participants in the mepivacaine group were satisfied with the pain relief, compared to 55% in the placebo group. The study authors, led by Dr. Anna Svensson from the Karolinska University Hospital in Stockholm, concluded that mepivacaine instillation is a safe and effective method for reducing procedural pain associated with IUD insertion, potentially improving patient acceptance and adherence to long-acting reversible contraception.

IUDs are a highly effective form of reversible contraception, but the pain associated with their insertion can be a significant barrier for some individuals. Current pain management strategies often include oral analgesics or cervical blocks, which have variable efficacy. The findings of this trial suggest that intrauterine mepivacaine instillation offers a promising alternative or adjunct to existing methods. The procedure involves a simple instillation of the anesthetic solution directly into the uterus using a thin catheter, which is performed by a healthcare provider. The anesthetic takes effect within minutes, providing local numbing of the uterine lining and cervix, which are the primary sites of pain during IUD placement. Further research may explore optimal dosages and timing for mepivacaine instillation, as well as its effectiveness in different patient populations or with various types of IUDs.